Heidelberg PHARMA
Focused Cancer Therapies



ATACs: Unique New Mode of Action to Fight Cancer

27th March 2023

FY 2022 Financial Results & Business Update

Safe Harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.

Agenda

- Corporate Overview & Highlights
- ATAC Technology & Proprietary Projects
- Financials
- Outlook

Heidelberg Pharma – a Clinical Stage Company

Our Company

~ 110 employees

Headquarters in **Heidelberg** area, Germany

Listed on Frankfurt Stock Exchange: HPHA

Clinical stage biotech

Complete **in-house research** capabilities

Cash reach until mid-2025

(as of March 2023)

Our Approach

Inhibition of RNA Polymerase II

Targeted delivery via antibodies **(ADC technology)**

Use **Amanitin** as toxic payload **(ATAC technology)**

Our Mission

Provide new options in cancer therapy

Overcome resistance mechanisms

Kill dormant tumor cells

Develop biomarker for patient stratification

Growing Pipeline of Proprietary and Partnered Programs

	Product	Target	Indication	Research	Preclinic	Phase I	Phase II	Phase III	Partner
ATAC pipeline	HDP-101	BCMA	Multiple Myeloma (DBCL/CLL)						Huadong (Asia)
	HDP-102	CD37	NHL						Huadong (Asia, option)
	HDP-103	PSMA	Prostate cancer						Huadong (Asia)
	HDP-104	GCC	Gastrointestinal (e.g. CRC)						Huadong (Asia, option)
	HDP-XX	n/a	Solid & hematological malignancies						Proprietary
ATAC partners	MGTA-ATACs	CD117, CD45	HSCs, conditioning programs for blood cancers and genetic diseases						Magenta ***All programs stopped***
	TAK-ATAC	n/a	Oncology						Takeda
	CHIOME-ATAC	CDCP1	Oncology						Chiome
Legacy assets	TLX250-CDx	CA-IX	Renal and urothelial carcinoma, TNBC						Telix
	TLX250	CA-IX	Renal carcinoma						Telix
	RHB-107		Oncology/GI, Covid-19						RedHill
	LH011		Pancreatic						Link Health

Highlights 2022 – Corporate Update

Strategic partnership with Huadong Medicine (February/September 2022)

Exclusive licensing agreement for Asia*

- Exclusive development and commercialization rights for HDP-101 and HDP-103; deal value: **up to USD 469 m + royalties**
- Exclusive option for HDP-102 and HDP-104; deal value: **up to USD 461 m + royalties**
- Next 2 ATAC candidates: Right of first negotiation (ROFN)

Investment Agreement

- Equity investment of **€ 105 m** in Heidelberg Pharma
- 2 seats in Supervisory Board

USD 1 bn
transaction volume

ATAC Technology Collaborations

Research and option agreement for an ATAC with Chiome (July 2022):

Couple amanitin to an antibody that targets CDCP1, expressed on many solid tumors

License agreement for an ATAC with Takeda (September 2022):

Worldwide exclusive license for an ATAC targeting a previously selected target molecule (not disclosed)

* People's Republic of China, Hong Kong, Macao, Taiwan, South Korea, Indonesia, Singapore, The Philippines, Thailand, Bangladesh, Bhutan, Brunei, Myanmar, Cambodia, Laos, Malaysia, Maldives, Mongolia, Nepal and Vietnam; excludes Japan, India, Pakistan, Sri Lanka

Highlights 2022 – Proprietary ATAC Programs

HDP-101 – first-in-human study in Multiple Myeloma patients with a completely new mode of action

- First patient dosed (Feb 2022)
- Preliminary safety data presented at ASH Annual Meeting 2022 (Dec 2022)

Preclinical candidates HDP-102 and HDP-103 advanced during 2022

- Production of antibody material for toxicology testing completed
- Production of toxin linker in non-GMP and GMP quality to be used for GLP and clinical Phase I studies
- Further preclinical and toxicology studies carried out

HDP-104: new ATAC targeting guanylyl cyclase C (GCC) revealed Fall of 2022

- Indication: gastrointestinal tumors

New preclinical data from the ATAC technology platform presented at the AACR 2022 Annual Meeting showing …

- the synergy of using ATACs together with immune checkpoint inhibitors and
- indicating that repeated treatment with ATACs in preclinical models results in better tolerability without compromising efficacy.

Highlights 2022 - Legacy Portfolio: Partner Telix - Progressing towards Filing for Market Approval

Pivotal Phase III ZIRCON reported positive topline results with imaging agent TLX250-CDx in November 2022

Accurate diagnosis of clear cell renal cell carcinoma (ccRCC) with TLX250-CDx (89Zr-DFO-girentuximab)

- Global multicenter Ph III trial with 300 patients with renal masses
- Imaging compared to histology of surgically obtained tissue (standard of truth)

Pivotal trial met all endpoints:

- 86% sensitivity, 87% specificity and 93% positive predictive value
- 85% sensitivity and 89% specificity in detecting ccRCC in tumors <4 cm

Next steps:

- Filing for regulatory approval with the FDA and other agencies
- Telix plans with potential marketing approval and launch in 2024
- **Indication expansion:**
  Ongoing Ph I and II studies in bladder cancer and in triple-negative breast cancer





ATAC Technology & Proprietary Projects

Lead Program: HDP-101 in Multiple Myeloma

Multiple Myeloma (MM)

- 70,000 deaths annually
- Median survival ~47-110 months
- Characterized by the proliferation of single clone of plasma cells derived from B-cells
- BCMA (B-cell maturation antigen) overexpression and activation are associated with MM





Source: healthcare-in-europe.com



Source: Heidelberg Pharma

HDP-101: Anti-BCMA-ATAC

- Targeted elimination of BCMA-containing cells with favorable preclinical toxicity profile
- Higher potency in cells with 17p deletions, which are associated with aggressive disease
- Clinical trial started in Feb 2022
- Phase I dose escalation study ongoing

First-in-Human Clinical Trial with an ATAC ongoing

HDP-101: anti-BCMA-ATAC for multiple myeloma

Two-part, open-label, multicenter Phase I/IIa study to determine safe dose and assess preliminary efficacy



Trial sites active and enrolling*:

US
- MD Anderson, Houston
- Emory University, Atlanta
- Mount Sinai Hospital, New York

DE
- University Hospital Heidelberg
- University Hospital Mainz
- University Hospital Kiel

*Further US and European sites currently being opened

Trial status:

- Three patient cohorts (20, 30, and 60 µg/kg) completed so far, 8 patients in total
- Latest review by Safety Review Committee in March:
  - Treatment is safe and well-tolerated in these three cohorts
  - Continue dose escalation
  - Discussion of Magenta events: no indication that they were related to the ATAC platform
    - Implementation of additional precautionary safety measures recommended to maximize the safety of the patients

Further ATAC Candidates: HDP-102, HDP-103 and HDP-104

HDP-102: anti-CD37-ATAC

- CD37 is overexpressed on B-cell lymphoma cells
- Specific indication of non-Hodgkin lymphoma (NHL)
- High prevalence of 17p deletion in NHL
- ASH (Dec 2021): High efficacy of anti-CD37-ATAC in Richter's syndrome xenograft model

HDP-103: anti-PSMA-ATAC

- PSMA is overexpressed in nearly all cases of prostate cancer; limited expression in normal tissue
- Target indication is Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prevalence of 17p deletion in mCRPC is 60%
- 17p biomarker has been validated preclinically for prostate cancer (Nature Commun. 2018 22:4394)

HDP-104: anti-GCC-ATAC

- Guanylyl cyclase C (GCC) is a transmembrane receptor protein (GUCY2C) for regulation of intestinal electrolyte homeostasis
- (Over-) Expressed in >95% of colorectal cancer, and in ~ 65% of esophageal, gastric, and pancreatic tumors
- Indication: gastrointestinal tumors
- Generating IP and Preparation for preclinical development

Potential IND application in 2024 for HDP-102 and HDP-103



Financials

Profit and Loss 2022

in € m	Guidance 10/2022	FYR 2022	FYR 2021	Change
Sales revenue and other income	18.5 – 20.5	19.9	2.3	765%
Operating expenses	**35.0 – 39.0**	**37.0**	**27.9**	**33%**
Cost of sales		4.7	4.7	0%
R&D costs		26.4	18.7	41%
Administrative costs		4.8	4.0	20%
Other expenses		1.1	0.5	120%
Operating result (EBIT)	**(16.0) – (20.0)**	**17.2**	**25.6**	**-33%**
Net loss for the period		**19.7**	**26.1**	**-25%**

Operating expenses



- Financials in line with adjusted guidance
- Sales revenue significantly higher due to upfront payment by Huadong
- Operating expenses including depreciation and amortization increased principally because research and development costs increased in line with planning
- Net loss lower than 2021 due to higher sales revenue and lower operating expenses than originally planned

Balance Sheet and Cash 2022

Financings 2022

- €5 m shareholder loan from dievini in February 2022
- €80 m gross proceeds from rights issue in September 2022
  - Issue of 12.4 million new shares at €6.44
  - Huadong becomes 2nd largest shareholder (35%) by participation in rights issue and additional share purchase from dievini

Assets (€ m)	30.11.2022	30.11.2021
Non-current assets	12.7	12.7
Other current assets	6.6	2.9
Cash and cash equivalents	81.3	6.1
	100.6	**21.7**

Equity and liabilities (€ m)	30.11.2022	30.11.2021
Current liabilities	28.0	14.9
Non-current liabilities	6.0	0.1
Equity	66.6	6.7
	100.6	**21.7**

- Cash balance at 30th Nov. 2022: €81.3 m (2021: €6.1 m)
- Average cash usage per month €0.7 m (Guidance: €2.7 to 3.1 m; 2021: €2.3 m)
- Equity year-end 2022 increased to €66.6 m (2021: €6.7 m)
- Equity ratio was 66.3% (2021: 30.8%)



Outlook

Next Steps Proprietary ATAC Pipeline
High Priority and Focus on HDP-101 to Advance Validation

HDP-101

Phase I/IIa study in RRMM

- Dose escalation ongoing, further study centers in Poland and Hungary
- Implementation of additional precautionary safety measures
- Next dose cohort will be opened with the added modifications
- Phase I completion in early 2024 and dose finding for Phase IIa
- Start Phase IIa part in 2024

HDP-102

CD37-ATAC for NHL

- Completion of preclinical and toxicological studies
- IND 2024

HDP-103

PSMA-ATAC for prostate cancer

- Completion of preclinical and toxicological studies
- IND 2024

HDP-104

Guanylyl cyclase C (GCC)-ATAC for colorectal cancer

- Focus on generating IP
- Preclinical start in preparation

Guidance 2023

in € m	Actual 2022	Guidance 2023
Sales revenue and other income	19.9	7.0 to 10.0
Operating expenses	37.0	37.0 to 41.0
Operating result (EBIT)	(17.2)	(28.5) to (32.5)
Funds required	8.9	32.5 to 36.5
Funds required per month	0.7	2.7 to 3.1

- Cash reach is secured until mid-2025 based on current budget planning

Investment Summary

A clinical-stage company with the goal of becoming a global ADC player

Disruptive first-in-humans mode of action provides **high efficacy** and **potential for unique clinical advantages**

Heidelberg PHARMA
Focused Cancer Therapies

Validated by international **high-quality partnerships**

Clinical lead program with **best-in-class potential** for indication with high medical need

Increased efficacy against certain aggressive tumors based on **biomarker**

Strategic partnership for Asia, fastest growing pharmaceutical market

High value potential with growing ATAC pipeline and attractive ADC environment



Q & A

Heidelberg Pharma AG
Ladenburg, Germany
Tel.: +49 6203 10090
investors@hdpharma.com
www.heidelberg-pharma.com